Antimicrob Agents Chemother. 2006 Dec;50(12):4182-5. Epub 2006 Oct 2.

High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.

Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S, Oliveira M, Moisi D, Ndwapi N, Moffat H, Essex M, Wainberg MA.

Source

Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana.

Abstract

We analyzed the reverse transcriptase genotypes of human immunodeficiency virus type 1 subtype C viruses isolated from 23 patients in Botswana treated with didanosine-based regimens. The K65R mutation was selected either alone or together with the Q151M, S68G, or F116Y substitution in viruses from seven such individuals. The results of in vitro passage experiments were consistent with an apparent increased propensity of subtype C viruses to develop the K65R substitution.

PMID:: 17015626; [PubMed - indexed for MEDLINE]
PMCID: PMC1693987

Free PMC Article

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Libraries

LinkOut Holdings

Supplemental Content

Related citations

Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel. [J Med Virol. 2009]
Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.
Turner D, Shahar E, Katchman E, Kedem E, Matus N, Katzir M, Hassoun G, Pollack S, Kessner R, Wainberg MA, et al. J Med Virol. 2009 Sep; 81(9):1509-12.
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. [J Acquir Immune Defic Syndr. 2008]
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Svarovskaia ES, Feng JY, Margot NA, Myrick F, Goodman D, Ly JK, White KL, Kutty N, Wang R, Borroto-Esoda K, et al. J Acquir Immune Defic Syndr. 2008 Aug 1; 48(4):428-36.
Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. [Antivir Ther. 2008]
Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
McColl DJ, Chappey C, Parkin NT, Miller MD. Antivir Ther. 2008; 13(2):189-97.
Review Didanosine enteric-coated capsule: current role in patients with HIV-1 infection. [Drugs. 2007]
Review Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.
Moreno S, Hernández B, Dronda F. Drugs. 2007; 67(10):1441-62.
Review Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects. [Curr Med Chem. 2006]
Review Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
Bongiovanni M, Tordato F. Curr Med Chem. 2006; 13(23):2789-93.

See reviews... See all...

Cited by 28 PubMed Central articles

HIV Genetic Diversity and Drug Resistance. [Viruses. 2010]
HIV Genetic Diversity and Drug Resistance.
Santos AF, Soares MA. Viruses. 2010 Feb; 2(2):503-31. Epub 2010 Feb 2.
Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs. [Viruses. 2010]
Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.
Wainberg MA, Brenner BG. Viruses. 2010 Nov; 2(11):2493-508. Epub 2010 Nov 11.
A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. [PLoS One. 2011]
A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1.
Coutsinos D, Invernizzi CF, Moisi D, Oliveira M, Martinez-Cajas JL, Brenner BG, Wainberg MA. PLoS One. 2011; 6(5):e20208. Epub 2011 May 31.

See all...

Chemical compound information

Didanosine

MW: 236.22 g/mol

MF: C₁₀H₁₂N₄O₃

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Nucleotide
Primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Taxonomy via GenBank
Taxonomy records associated with the current articles through taxonomic information on related molecular database records (Nucleotide, Protein, Gene, SNP, Structure).
Protein
Protein translation features of primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
PopSet
Sets of sequences from population and evolutionary genetic studies in the PopSet database reported in the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

High prevalence of the K65R mutation in human immunodeficiency virus type 1 subt...
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.
Antimicrob Agents Chemother. 2006 Dec ;50(12):4182-5. Epub 2006 Oct 2 .

PubMed
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF0...
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
J Acquir Immune Defic Syndr. 2007 Sep 1 ;46(1):48-55.

PubMed
The public health approach to identify antiretroviral therapy failure: high-leve...
The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.
AIDS. 2009 Jun 1 ;23(9):1127-34.

PubMed
The macrophage in HIV-1 infection: from activation to deactivation?
The macrophage in HIV-1 infection: from activation to deactivation?
Retrovirology. 2010 Apr 9 ;7:33.

PubMed
Intrahost variations in the envelope receptor-binding domain (RBD) of HTLV-1 and...
Intrahost variations in the envelope receptor-binding domain (RBD) of HTLV-1 and STLV-1 primary isolates.
Retrovirology. 2006 May 25 ;3:29.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: